{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"51.9551","value":"75.050"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"}],"units":"Participants"}],"title":"Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"43.6019","value":"78.437"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"140"}],"units":"Participants"}],"title":"Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.1500","value":"91.081"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"title":"Day 84"}],"denoms":[{"counts":[{"groupId":"OG000","value":"141"}],"units":"Participants"}],"description":"MMR was defined as a ratio of BCR-ABL/ABL \\<=0.1% on the international scale (\\>=3 log reduction from standardized baseline in ratio of BCR-ABL to ABL transcripts) by quantitative RT-qPCR. Trough plasma concentration of participants who had MMR are presented in this outcome measure.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Philadelphia chromosome-positive CML received bosutinib tablets at a dose of 400 mg, orally once daily in the core treatment phase of 12 months and continued the same treatment into the extension phase or followed up for safety for up to approximately 4 years, until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.","id":"OG000","title":"Bosutinib"}],"paramType":"MEAN","populationDescription":"PK population included all enrolled participants who received at least 1 dose of bosutinib and had sufficient plasma results available. Here, \"N\" signifies number of participants evaluable for this outcome measure and \"n\" signifies participants evaluable at specified time points only. Data for this outcome measure was not planned to be collected and analyzed for Imatinib arm as pre-specified in the protocol.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Days 28, 56 and 84","title":"Summary of Trough Plasma Concentration by Major Molecular Response (MMR) of Bosutinib","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"ng/mL"}